Table 10 Sensitivity analysis of net budget impact of ustekinumab per patient (€)
From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
Base case | −443 | −674 | −786 | −847 | −900 |
Non-responders’ outpatient costs | |||||
−10% | −443 | −673 | −785 | −846 | −899 |
+10% | −444 | −674 | −786 | −848 | −901 |
Non-responders’ hospitalization costs | |||||
−10% | −417 | −647 | −759 | −820 | −873 |
+10% | −470 | −700 | −812 | −874 | −927 |
Ustekinumab share | |||||
−5% | −340 | −559 | −671 | −732 | −785 |
+5% | −547 | −789 | −901 | −962 | −1,015 |
−10% | −254 | −441 | −552 | −614 | −665 |
+10% | −648 | −906 | −1,018 | −1,080 | −1,133 |